Herantis Pharma

1.61 EUR

-2.42 %

Corporate customer

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

4,215 following

Compare

-2.42%

+21.97%

+7.69%

-2.72%

+2.22%

+3.21%

-28.57%

-78.16%

-84.01%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Market cap

32.46M EUR

Turnover

20.64K EUR

P/E (adj.) (24e)

EV/EBIT (adj.) (24e)

P/B (24e)

EV/S (24e)

Dividend yield-% (24e)

Coverage

Recommendation

Accumulate

Target price

Updated

23.08.2024

Disclaimer

Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Financial calendar

6.3.

2025

Annual report '24

24.4.

2025

General meeting '24

21.8.

2025

Interim report Q2'25

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Drug development investment: Value creation through M&As and licensing agreements

Article12/19/2024, 11:07 AM by

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatory press release12/12/2024, 2:00 PM

Herantis Pharma’s financial calendar and annual general meeting for 2025

Herantis Pharma

Regulatory press release12/10/2024, 4:30 PM

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Create account

Video12/3/2024, 12:50 PM

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma

Analyst Comment12/3/2024, 6:52 AM

Life Science Night available on inderesTV

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Webcast12/2/2024, 2:00 PM

Life Science Night | December 2, 2024

Welcome to follow Life Science Night on Monday, December 2 at 4:00 pm EET on inderesTV.

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Analyst Comment12/3/2024, 10:21 AM by

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analyst Comment11/12/2024, 6:53 AM by

Antti Siltanen

Part 1 of the Herantis trial completed

Herantis issued a press release on Monday announcing the completion of the Part 1 of the Phase Ib clinical trial of the drug candidate HER-096 in healthy volunteers.

Herantis Pharma

Press release11/11/2024, 3:05 PM

Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial

Herantis Pharma

Press release11/4/2024, 10:00 AM

Herantis Pharma Oyj: Herantis Pharma will present at the BioStock Life Science Summit, November 20

Herantis Pharma

Analyst Comment10/24/2024, 5:48 AM by

Antti Siltanen

Herantis R&D webinar complemented scientific background and roadmap

Herantis organized a webinar on Wednesday to discuss the base research, clinical trial program and financial status of HER-096.

Herantis Pharma

Press release10/23/2024, 5:30 AM

Herantis Pharma: Key messages from today’s R&D webinar

Herantis Pharma

Analyst Comment10/17/2024, 5:28 AM by

Antti Siltanen

Herantis clinical trial started as planned

Herantis issued a press release on Wednesday stating that HER-096 dosing has started in the Phase Ib trial.

Herantis Pharma

Press release10/16/2024, 7:30 AM

Herantis Pharma: HER-096 dosing started in the Phase 1b trial

Herantis Pharma

Press release10/8/2024, 5:00 AM

Herantis Pharma to host R&D webinar on October 23, 2024

Herantis Pharma

Regulatory press release10/2/2024, 10:15 AM

Composition of Herantis Pharma Plc's Shareholders' Nomination Committee

Herantis Pharma

Probabilities of success in drug development

Article9/26/2024, 1:26 PM by

Antti Siltanen

Probabilities of success in drug development

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Faron Pharmaceuticals Herantis Pharma Mendus

Analyst Comment9/20/2024, 6:10 AM by

Antti Siltanen